Bergom, Hannah E.
Sena, Laura A.
Day, Abderrahman
Miller, Benjamin
Miller, Carly D.
Lozada, John R.
Zorko, Nicholas
Wang, Jinhua
Shenderov, Eugene
Lobo, Francisco Pereira
Caramella-Pereira, Fernanda
Marchionni, Luigi http://orcid.org/0000-0002-7336-8071
Drake, Charles G.
Lotan, Tamara
De Marzo, Angelo M.
Hwang, Justin
Antonarakis, Emmanuel S.
Article History
Received: 24 July 2023
Accepted: 4 January 2024
First Online: 22 January 2024
Competing interests
: L.A.S. has received research funding to her institution from Panbela Therapeutics. N.Z. is a consultant to Caris Life Sciences and Telix Pharmaceuticals. E.S.A. is a paid consultant to GT Biopharma, Guidepoint Global, FirstThought, GLG and CapitalOne Securities, and receives institutional research funding from MacroGenics, Inc. C.G.D. is a paid employee of Janssen Research and Development. J.H is a paid consultant/advisor to Caris Life Sciences and Astrin Biosciences. E.S.A. is a paid consultant/advisor to Janssen, Astellas, Sanofi, Dendreon, Pfizer, Amgen, Eli Lilly, Bayer, AstraZeneca, Bristol Myers Squibb, ESSA, Clovis, Merck, Curium, Blue Earth Diagnostics, Foundation Medicine, Exact Sciences and Invitae; has received research funding to his institution from Janssen, Johnson & Johnson, Sanofi, Dendreon, Genentech, Novartis, Tokai, Bristol Myers Squibb, Constellation, Bayer, AstraZeneca, Clovis and Merck; and is the coinventor of a patented AR-V7 biomarker technology that has been licensed to Qiagen. The other authors declare no competing interests.